Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: ANXA1

Summary for ANXA1

Gene information	Gene symbol	ANXA1
	Ensembl ID	ENSG00000135046
	Entrez ID	301
	Gene name	annexin A1
	Synonyms	ANX1\|LPC1
	Gene type	protein_coding
	UniProtAcc	P04083

Top

Dataset with differentially expressed gene: ANXA1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	0.740179	7.58e-04
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.415914	3.94e-18
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.440577	4.81e-07
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.423226	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.251289	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.422336	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.295691	1.40e-45
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.704768	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	-0.313153	1.12e-44
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.273783	1.24e-15
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.898387	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.534587	2.12e-30
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.553587	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.451146	2.77e-06
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.253791	5.61e-45
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.515991	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.455911	4.64e-02
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.297165	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.592121	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-1.65483	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-2.24869	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.79139	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.677684	3.59e-13
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.272959	2.21e-23
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	-0.253368	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.275685	1.43e-22
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.252438	1.85e-23
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.25349	1.85e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.508647	5.01e-19
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	1.1659	1.50e-42
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.566672	1.43e-15
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	1.69196	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.314978	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-1.50062	0.00e+00
GSE158457	PDX cells	Cell line	Acute lymphoblastic leukemia	T-cell acute lymphoblastic leukemia (ALL)	Targeted therapy	dasatinib	NA	Malignant cells	-0.405159	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.552978	2.13e-43
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.340373	4.84e-13
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.371898	2.40e-09
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	NK cells	-0.39027	2.12e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.81934	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	1.13565	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.487642	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.835878	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.390199	1.66e-15
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.651122	3.36e-32
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.697866	6.12e-23
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.776902	2.54e-41
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.614179	7.98e-19
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.318942	1.67e-36
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.566476	1.62e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.315035	4.22e-13
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.254043	1.16e-17
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	0.437267	0.00e+00

Top

Expression of ANXA1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ANXA1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
ANXA1	NK cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	Mono/Macro	GSE111014	post	resistant
ANXA1	NK cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	Mono/Macro	GSE111014	post	sensitive
ANXA1	CD8+ T cells	CPI-SS030BB46BB	ANXA1_FPR2	ANXA1	FPR2	False	CD8+ T cells	Mono/Macro	GSE161801_IMiD	post	resistant
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	Mono/Macro	GSE161801_IMiD	post	resistant
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	cDCs	GSE161801_IMiD	post	resistant
ANXA1	CD4+ T cells	CPI-SS030BB46BB	ANXA1_FPR2	ANXA1	FPR2	False	CD4+ T cells	Mono/Macro	GSE161801_IMiD	post	resistant
ANXA1	CD4+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	Mono/Macro	GSE161801_IMiD	post	resistant
ANXA1	CD4+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	cDCs	GSE161801_IMiD	post	resistant
ANXA1	NK cells	CPI-SS030BB46BB	ANXA1_FPR2	ANXA1	FPR2	False	NK cells	Mono/Macro	GSE161801_IMiD	pre	resistant
ANXA1	NK cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	Mono/Macro	GSE161801_IMiD	pre	resistant
ANXA1	NK cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	cDCs	GSE161801_IMiD	pre	resistant
ANXA1	CD8+ T cells	CPI-SS030BB46BB	ANXA1_FPR2	ANXA1	FPR2	False	CD8+ T cells	Mono/Macro	GSE161801_PI	pre	resistant
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	Mono/Macro	GSE161801_PI	pre	resistant
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	cDCs	GSE161801_PI	pre	resistant
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	Malignant cells	cDCs	GSE162117	post	sensitive
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	cDCs	Malignant cells	GSE162117	post	sensitive
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	cDCs	cDCs	GSE162117	post	sensitive
ANXA1	NK cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	Malignant cells	GSE162117	pre	sensitive
ANXA1	Mono/Macro	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	Mono/Macro	GSE164551	NA	resistant
ANXA1	Mono/Macro	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	Mono/Macro	GSE164551	NA	resistant
ANXA1	Mono/Macro	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	Mono/Macro	Mono/Macro	GSE164551	NA	resistant
ANXA1	Mono/Macro	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	Mono/Macro	Mono/Macro	GSE164551	NA	sensitive
ANXA1	CD4+ T cells	CPI-SS030BB46BB	ANXA1_FPR2	ANXA1	FPR2	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteBlood	pre	resistant
ANXA1	CD4+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteBlood	pre	resistant
ANXA1	CD4+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	cDCs	GSE169246_PacAteBlood	pre	resistant
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	cDCs	GSE169246_PacAteBlood	pre	resistant
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	cDCs	GSE169246_PacAteBlood	pre	resistant
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	Mono/Macro	cDCs	GSE169246_PacAteBlood	pre	resistant
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	cDCs	GSE169246_PacAteBlood	pre	resistant
ANXA1	cDCs	CPI-SS030BB46BB	ANXA1_FPR2	ANXA1	FPR2	False	cDCs	Mono/Macro	GSE169246_PacAteBlood	pre	resistant
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	cDCs	Mono/Macro	GSE169246_PacAteBlood	pre	resistant
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	cDCs	cDCs	GSE169246_PacAteBlood	pre	resistant
ANXA1	CD4+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteBlood	pre	sensitive
ANXA1	cDCs	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	cDCs	Mono/Macro	GSE169246_PacAteBlood	pre	sensitive
ANXA1	NK cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	Mono/Macro	GSE169246_PacAteTissue	post	resistant
ANXA1	NK cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	NK cells	Mono/Macro	GSE169246_PacAteTissue	post	resistant
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	resistant
ANXA1	CD8+ T cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	resistant
ANXA1	CD4+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	resistant
ANXA1	CD4+ T cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	resistant
ANXA1	CD4+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
ANXA1	NK cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	NK cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
ANXA1	NK cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	NK cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
ANXA1	CD8+ T cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
ANXA1	CD4+ T cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	CD4+ T cells	Mono/Macro	GSE169246_PacAteTissue	post	sensitive
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	pre	resistant
ANXA1	CD8+ T cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	CD8+ T cells	Mono/Macro	GSE169246_PacAteTissue	pre	resistant
ANXA1	CD8+ T cells	CPI-SS0F739D3DB	ANXA1_FPR1	ANXA1	FPR1	False	CD8+ T cells	cDCs	GSE169246_PacAteTissue	pre	resistant
ANXA1	CD8+ T cells	CPI-SS06CCF5A54	ANXA1_FPR3	ANXA1	FPR3	False	CD8+ T cells	cDCs	GSE169246_PacAteTissue	pre	resistant

Page: 1 2 3 4 5

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
ANXA1	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating ANXA1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ANXA1	hsa-miR-5690	93.2421	NM_000700
ANXA1	hsa-miR-1185-2-3p	92.6282	NM_000700
ANXA1	hsa-miR-1185-1-3p	92.6282	NM_000700
ANXA1	hsa-let-7f-2-3p	92.6282	NM_000700
ANXA1	hsa-miR-3124-3p	90.8396	NM_000700
ANXA1	hsa-miR-5692c	89.9551	NM_000700
ANXA1	hsa-miR-5692b	89.9551	NM_000700
ANXA1	hsa-miR-153-5p	88.9053	NM_000700
ANXA1	hsa-miR-1277-5p	84.2885	NM_000700
ANXA1	hsa-miR-4797-5p	84.1513	NM_000700
ANXA1	hsa-miR-3192-3p	81.4467	NM_000700
ANXA1	hsa-miR-3675-3p	80.9746	NM_000700
ANXA1	hsa-miR-450a-2-3p	80.6574	NM_000700
ANXA1	hsa-miR-3163	80.207	NM_000700

Page: 1

Top

Motifs and transcription factors (TFs) regulating ANXA1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ANXA1	metacluster_191.2	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).
ANXA1	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
ANXA1	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
ANXA1	cisbp__M08198	ELF1 (directAnnotation).
ANXA1	metacluster_50.1	BATF; BATF; BATF; BATF; BNC2; FOS; FOSB; FOSL1; FOSL1; IRF4; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMAD2; SMAD3 (directAnnotation). BATF; BATF; BATF; FOS; FOSL1; FOSL2; JDP2; JUN; JUN; JUND (inferredBy_Orthology).
ANXA1	metacluster_157.2	ATF3; ATF3; ATF3; BACH1; BACH1; BACH1; BACH2; BACH2; BACH2; BACH2; BATF; BATF; BCL11A; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; MAF; MAFB; MAFF; MAFG; MAFK; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2; NFE2L3; ZNF3; ZSCAN5C (directAnnotation). FOSL1; JUN; JUN; JUN; JUNB; JUNB; JUND (inferredBy_Orthology).
ANXA1	homer__TAATCCCN_Pitx1	PITX1 (inferredBy_Orthology).
ANXA1	transfac_pro__M05688	ZNF133 (directAnnotation).
ANXA1	taipale_tf_pairs__GCM1_HOXA2_RTRSGGGNNTAATKR_CAP_repr	GCM1; HOXA2 (directAnnotation).
ANXA1	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_1	DLX2; ERF (directAnnotation).
ANXA1	metacluster_22.19	NFE2 (directAnnotation).
ANXA1	metacluster_22.37	BACH1 (directAnnotation).
ANXA1	metacluster_22.36	BACH2 (directAnnotation).
ANXA1	dbtfbs__SETDB1_HEK293_ENCSR348AGV_merged_N1	SETDB1 (directAnnotation).
ANXA1	metacluster_22.30	NFE2L2 (directAnnotation).
ANXA1	taipale_tf_pairs__ETV2_DLX2_RCCGGAANNNNNYAATTA_CAP	DLX2; ETV2 (directAnnotation).
ANXA1	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_2	DLX2; ERF (directAnnotation).
ANXA1	transfac_pro__M05846	ZNF689 (directAnnotation).
ANXA1	metacluster_137.2	ATF3; BACH2; BATF; BATF; BATF; BATF; BATF3; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSB; FOSB; FOSB; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; INSM2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMARCC1 (directAnnotation). ATF3; ATF3; BATF; FOS; FOSB; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUND; JUND; JUND; JUND (inferredBy_Orthology).
ANXA1	taipale_tf_pairs__FLI1_DLX2_ACCGGAARTNNNYAATTA_HT	DLX2; FLI1 (directAnnotation).
ANXA1	metacluster_22.12	NFE2; NFE2L1 (directAnnotation).
ANXA1	metacluster_23.11	ZNF552 (directAnnotation).
ANXA1	metacluster_9.9	EMX2 (directAnnotation).
ANXA1	metacluster_22.28	BACH1 (directAnnotation).
ANXA1	tfdimers__MD00432	DBP; STAT1 (directAnnotation).
ANXA1	kznf__ZNF490_Schmitges2016_ChIP-seq	ZNF490 (directAnnotation).
ANXA1	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
ANXA1	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
ANXA1	taipale_tf_pairs__ATF4_CEBPD_NGATGATGCAATNN_CAP	ATF4; CEBPD (directAnnotation).
ANXA1	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
ANXA1	transfac_public__M00280	RFX1 (directAnnotation).
ANXA1	transfac_pro__M01251	E2F1 (directAnnotation).
ANXA1	tfdimers__MD00186	NFATC3; SPI1 (directAnnotation).
ANXA1	taipale_tf_pairs__ETV2_SOX15_RSCGGAWNNNNNNNACAATRN_CAP_repr	ETV2; SOX15 (directAnnotation).
ANXA1	taipale_tf_pairs__PBX4_HOXA10_CCATAAATCA_CAP	HOXA10; PBX4 (directAnnotation).
ANXA1	metacluster_21.4	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
ANXA1	taipale_tf_pairs__ATF4_CEBPB_NNATGAYGCAAYN_CAP	ATF4; CEBPB (directAnnotation).
ANXA1	transfac_pro__M05542	SNAPC4 (directAnnotation).
ANXA1	transfac_pro__M05347	NR2C1 (directAnnotation).
ANXA1	metacluster_130.9	ZNF569 (directAnnotation). ZNF569 (inferredBy_Orthology).
ANXA1	taipale_cyt_meth__PITX2_YTAATCCN_FL	PITX2 (directAnnotation).
ANXA1	transfac_pro__M06129	GLI4 (directAnnotation).
ANXA1	hdpi__NFIX	NFIX (directAnnotation).
ANXA1	hdpi__FOXM1	FOXM1 (directAnnotation).
ANXA1	transfac_pro__M06857	ZNF611 (directAnnotation).
ANXA1	metacluster_172.10	ZNF18; ZNF417; ZNF587 (directAnnotation).
ANXA1	metacluster_155.21	ZNF454; ZNF454 (directAnnotation).
ANXA1	jaspar__MA1633.2	BACH1 (directAnnotation).
ANXA1	hdpi__ZNF193	ZSCAN9 (directAnnotation).
ANXA1	taipale_tf_pairs__ERF_ONECUT2_RSCGGAANNNNNNRTCGATN_CAP	ERF; ONECUT2 (directAnnotation).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
ANXA1	"Amcinonide"	DB00288	small molecule
ANXA1	"Betamethasone phosphate"	DB14669	small molecule
ANXA1	"Budesonide"	DB01222	small molecule
ANXA1	"Clobetasol propionate"	DB01013	small molecule
ANXA1	"Cortisone acetate"	DB01380	small molecule
ANXA1	"Dexamethasone acetate"	DB14649	small molecule
ANXA1	"Dexamethasone"	DB01234	small molecule
ANXA1	"Fluocinolone acetonide"	DB00591	small molecule
ANXA1	"Hydrocortisone aceponate"	DB14538	small molecule
ANXA1	"Hydrocortisone acetate"	DB14539	small molecule
ANXA1	"Hydrocortisone butyrate"	DB14540	small molecule
ANXA1	"Hydrocortisone cypionate"	DB14541	small molecule
ANXA1	"Hydrocortisone phosphate"	DB14542	small molecule
ANXA1	"Hydrocortisone probutate"	DB14543	small molecule
ANXA1	"Hydrocortisone valerate"	DB14544	small molecule
ANXA1	"Hydrocortisone"	DB00741	small molecule
ANXA1	"Methylprednisolone"	DB00959	small molecule
ANXA1	"Prednisolone phosphate"	DB14631	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."